v
Search
Advanced

Publications > Journals > Most Viewed Articles

Results per page:
v
Letter to the Editor Open Access
Wen-Wen Luo, Da-Long Yang, Jian-Hong Zhong, Yi-Li Ma, Zhen-Zhen Li
Published online November 16, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 38
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00709
Original Article Open Access
Jenny Gao, Yongfeng Zhang, Mary L. Disis, Lanjing Zhang
Published online October 30, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 25
Exploratory Research and Hypothesis in Medicine. doi:10.14218/ERHM.2026.00057
Abstract
Large language model (LLM)-assisted literature retrieval may lead to bibliographic errors that have not been rigorously quantified. Therefore, we aimed to analyze errors in reference [...] Read more.

Large language model (LLM)-assisted literature retrieval may lead to bibliographic errors that have not been rigorously quantified. Therefore, we aimed to analyze errors in reference retrieval of free-version LLMs and their associated factors.

We evaluated 2,000 references retrieved by 5 LLMs (Grok, ChatGPT, Gemini, Perplexity, and DeepSeek) for 40 randomly selected original articles (10 per journal) published from January 2024 to July 2025 in British Medical Journal, Journal of the American Medical Association, Lancet, and New England Journal of Medicine. The primary outcomes were the score ratio, a composite score of validity of digital object identifier, PubMed ID, Google Scholar link, and relevance, with a bonus point for retrieving the index article, and the complete miss status that indicated failures on all metrics. Multilevel mixed-effects multivariable regression was used.

References retrieved by LLMs failed all metrics 48.7% of the time. Grok was linked to a higher score ratio than ChatGPT (coefficient = 0.14, 95% confidence interval [CI], 0.07–0.21; P < 0.001), while all other platforms were associated with lower ones. Compared with ChatGPT, Grok was associated with lower odds of complete miss (better performance, odds ratio (OR) = 0.23, 95% CI, 0.11–0.46; P < 0.001), but DeepSeek, Gemini, and Perplexity were associated with higher odds (OR = 3.49, 95% CI, 1.87–6.50; OR = 16.86, 95% CI, 8.69–32.71; OR = 11.01, 95% CI, 5.79–20.94; respectively; P < 0.001 for all). Journals were linked to the score ratio, not complete miss.

We show that the performance of LLM-assisted literature search and retrieval in medicine is overall variable and often unreliable.

Full article
Review Article Open Access
Tian Li, Yong Yuan, Xiaofeng Li, Xiaoxia Hao
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 25
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00343
Abstract
Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), [...] Read more.

Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), a major bioactive constituent isolated from Astragalus mongholicus Bunge, exerts a broad range of pharmacological effects, including anti-inflammatory, antioxidant, and antifibrotic effects. This review synthesizes current evidence on the pharmacological characteristics, mechanistic basis, preclinical efficacy, and translational challenges of AS-IV in liver fibrosis. Available evidence indicates that AS-IV exerts its antifibrotic effects primarily by suppressing hepatic stellate cell activation, with modulation of transforming growth factor-β/Smad signaling representing the most consistently supported mechanism. Beyond this principal pathway, AS-IV may attenuate profibrotic amplification loops by enhancing antioxidant responses and suppressing inflammatory signaling, while also reducing upstream profibrotic stimuli through hepatoprotective effects. However, its clinical translation remains limited by poor oral bioavailability, inadequately defined pharmacokinetic-pharmacodynamic relationships, and a lack of high-quality clinical evidence. Overall, AS-IV represents a promising preclinical antifibrotic candidate, although clinical efficacy and pharmacological optimization remain to be established.

Full article
Review Article Open Access
He Ma, Jia-Rui Zheng, Xin-Kun Liu, Lin-Xiang Huang, Yan-Di Xie, Bo Feng
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 19
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00549
Abstract
Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected [...] Read more.

Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected functional cure of chronic hepatitis B following allogeneic hematopoietic stem cell transplantation provides a unique proof-of-principle model for immune-mediated HBsAg clearance. This review aims to elucidate that the core mechanism underlying hematopoietic stem cell transplantation-mediated HBsAg clearance lies in “adoptive immune transfer”, and to explore design principles and future directions for modern cell-based immunotherapies based on this mechanism. We reviewed available case reports and meta-analytic evidence, acknowledging their limitations, and dissected the immunological mechanisms by which donor-derived hepatitis B virus-specific T and B cells may jointly reconstitute adaptive immunity and break host immune tolerance. We then comparatively evaluated the technical characteristics and limitations of chimeric antigen receptor T cell therapy and T-cell receptor-engineered T-cell therapy. Current engineered T-cell therapies, while translating the core principle of adoptive transfer, exhibit fundamental limitations including monoclonal specificity, inability to remodel the host microenvironment, and absence of durable humoral reconstitution. A broader functional-cure strategy may require adopting the paradigm of synergy and systemic immune reshaping exemplified by hematopoietic stem cell transplantation. Future strategies should develop temporally optimized, multilayered combination therapies, offering a possible pathway for next-generation therapeutics capable of systemically rebuilding antiviral immunity.

Full article
Original Article Open Access
Fangqian Du, Xiangyan Zhang, Yuwei Xie, Hao Zou, Kun Li, Kui Liu, Praveena George, Bingzi Dong, Chengzhan Zhu
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 17
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00370
Abstract
Extrahepatic cholangiocarcinoma (eCCA) is often accompanied by biliary obstruction and alterations in bile composition, which may affect the tumor microenvironment. KPNB1 is a key [...] Read more.

Extrahepatic cholangiocarcinoma (eCCA) is often accompanied by biliary obstruction and alterations in bile composition, which may affect the tumor microenvironment. KPNB1 is a key nuclear transport receptor that is aberrantly expressed in various malignancies. However, KPNB1’s role in cholangiocarcinoma (CCA) remains unclear. In this study, we aimed to investigate the biological role and underlying molecular mechanisms of KPNB1 in CCA progression and explore its association with the biliary microenvironment.

To investigate the role of KPNB1 in CCA, we analyzed its expression and clinical significance using public databases and clinical specimens and performed a series of in vitro and in vivo functional experiments. The antitumor effects of the KPNB1 inhibitor importazole were assessed in vitro and in vivo. The KPNB1-LDHA-SOX2 signaling pathway was investigated using mass spectrometry, immunoprecipitation, and rescue assays. Furthermore, KPNB1 levels in bile were analyzed, and their clinical value was evaluated.

KPNB1 was markedly overexpressed in eCCA tissues and was associated with aggressive clinicopathological features and poor prognosis. Functional analyses demonstrated that KPNB1 enhanced CCA cell proliferation, migration, invasion, epithelial–mesenchymal transition, and stemness-related characteristics of CCA cells, whereas importazole significantly inhibited these malignant phenotypes and tumor growth. Mechanistically, KPNB1 enhanced the expression of stemness-related genes by promoting the nuclear accumulation of LDHA and its interaction with SOX2. Furthermore, eCCA-derived bile enhanced malignant phenotypes and KPNB1 protein expression in CCA cells, while eCCA bile-derived exosomes were enriched in KPNB1 and exerted similar tumor-promoting effects.

KPNB1 promotes cholangiocarcinoma progression through the KPNB1-LDHA-SOX2 axis and may contribute to tumor progression within the biliary microenvironment. Elevated KPNB1 levels in bile may have potential prognostic value, and targeting KPNB1 may represent a promising therapeutic strategy for cholangiocarcinoma.

Full article
Original Article Open Access
Khalid M. AlNaamani, Sultan AlBalushi, Mohamed El-Kassas, Hilal Alsabti, Siham AlSinani, Saleh A. Alqahtani, Khalid A. Alswat, Tarannum Behlim, Waleed K. Al-Hamoudi, Faisal M. Sanai, Faisal Abaalkhail, Saad A. AlGhamdi, Zobair M. Younossi
Published online November 17, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 16
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00740
Abstract
Across the Middle East and North Africa (MENA), the age-standardized rates (ASRs) of hepatitis B virus (HBV) burden may be declining while the absolute burden rises among middle-aged [...] Read more.

Across the Middle East and North Africa (MENA), the age-standardized rates (ASRs) of hepatitis B virus (HBV) burden may be declining while the absolute burden rises among middle-aged and older adults. In this study, we aimed to characterize changes in rates, counts, and age distribution across 21 MENA countries, with Oman as a case study.

We analyzed Global Burden of Disease 2023 estimates for 1990–2023. Disability-adjusted life-years (DALYs) were used to measure the overall HBV-related burden, and acute hepatitis B incidence was examined as a secondary outcome. We compared population-weighted means of country ASRs with aggregated counts, assessed rate-count divergence, and summarized DALYs across four fixed age bands.

The population-weighted mean DALY ASR declined 53.0%, from 624.5 to 293.6 per 100,000 (estimated annual percentage change −2.28%; 95% confidence interval −2.34 to −2.23), while absolute DALYs increased 19.3%, from 1.18 to 1.41 million. Mean burden age increased in 20 countries, by up to 12.4 years, and the 0–34-year DALY share declined in 19 countries. In Oman, DALYs and acute-incidence ASRs declined 38.6% and 49.2%, while DALYs at ages 35–54 increased 2.55-fold and represented 43.3% of national HBV DALYs in 2023.

HBV burden in MENA is shifting toward middle-aged and older adults while absolute DALYs rise despite declining ASRs. Service planning should consider counts and age distribution alongside rates, with sustained vaccination complemented by adult diagnosis, treatment, cirrhosis care, and hepatocellular carcinoma surveillance.

Full article
PrevPage 36 of 36 12…3233343536Next
Back to Top